Benzinga · Aug 24, 2026
Grace Therapeutics Files Prospectus For Offering 4.762M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1444192/000114036126034189/ny20080485x1_s3.htm
GR
NASDAQ · GRCE
Grace Therapeutics, Inc.
Healthcare · Biotechnology
$2.10
Down-$0.04 (-1.87%)
Updated Sep 6, 2026, 8:59 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.49M
- P/E ratio
- -6.84
- Dividend yield
- 0.00%
- 52-week range
- $1.79 – $5.18
- Volume
- 186.77K
- Avg. volume
- 65.65K
Price performance
GRCE price history
1M range · 20 trading sessions · Daily adjusted prices
GRCE closed at $2.10 after 20 trading sessions, down 0.47% for the selected period.
- Last close
- $2.10
- Period change
- -0.47%
- Period low
- $2.07
- Period high
- $2.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $2.12 | $2.1899 | $2.08 | $2.10 | 186.77K |
| Sep 3, 2026 | $2.15 | $2.20 | $2.07 | $2.14 | 159.23K |
| Sep 2, 2026 | $2.19 | $2.19 | $2.0969 | $2.14 | 48.98K |
| Sep 1, 2026 | $2.09 | $2.14 | $2.07 | $2.10 | 78.97K |
| Aug 31, 2026 | $2.1012 | $2.14 | $2.07 | $2.13 | 117.31K |
| Aug 28, 2026 | $2.16 | $2.16 | $2.12 | $2.12 | 66.11K |
| Aug 27, 2026 | $2.10 | $2.18 | $2.10 | $2.16 | 82.27K |
| Aug 26, 2026 | $2.20 | $2.20 | $2.14 | $2.15 | 22.21K |
| Aug 25, 2026 | $2.18 | $2.22 | $2.18 | $2.20 | 94.44K |
| Aug 24, 2026 | $2.23 | $2.23 | $2.13 | $2.18 | 86.6K |
| Aug 21, 2026 | $2.15 | $2.2299 | $2.15 | $2.20 | 75.91K |
| Aug 20, 2026 | $2.19 | $2.24 | $2.10 | $2.14 | 54.72K |
| Aug 19, 2026 | $2.16 | $2.21 | $2.1509 | $2.20 | 159.76K |
| Aug 18, 2026 | $2.17 | $2.17 | $2.04 | $2.13 | 103.94K |
| Aug 17, 2026 | $2.19 | $2.25 | $2.15 | $2.16 | 99.36K |
| Aug 14, 2026 | $2.06 | $2.19 | $2.02 | $2.16 | 397.81K |
| Aug 13, 2026 | $2.10 | $2.13 | $2.058 | $2.07 | 193.83K |
| Aug 12, 2026 | $2.13 | $2.13 | $2.06 | $2.10 | 121.84K |
| Aug 11, 2026 | $2.10 | $2.13 | $2.08 | $2.12 | 97.76K |
| Aug 10, 2026 | $2.13 | $2.16 | $2.075 | $2.11 | 184.32K |
Latest GRCE news
The latest Smart Investors Daily articles mentioning GRCE.
Stock researchCompany · Overview
GRCE research
Overview
Company profile and research snapshot.
Company profile
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $11.90
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 24, 2026 | TD Cowen | Buy | — |
| Feb 18, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per
Yahoo · Aug 5, 2026
Grace Therapeutics Announces $10 Million Private Placement
Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase
Benzinga · Jul 28, 2026
Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical DataCompany Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
